Aerolase Funding: How Much Did They Raise & Key Investors

How Much Did Aerolase Raise?
Funding & Key Investors

Aerolase, a prominent innovator in the medical aesthetics sector, has successfully secured significant capital to bolster its market presence. With a cumulative total of $2.2M, the company continues to demonstrate robust growth potential within the specialized dermatology technology landscape. This latest major strategic investment of $1.2M underscores investor confidence in the firm's proprietary high-power, portable laser platforms, which are increasingly becoming the standard for contactless dermatological care.

The trajectory of Aerolase reflects a disciplined approach to scaling, moving from initial debt-based financing rounds in 2020 to more substantial capital infusions by early 2021. This financial backing serves as a critical catalyst for the company as it seeks to expand its footprint in both clinical and aesthetic markets, ensuring that its unique, hygienic, and patient-centric technology remains at the forefront of modern medical practice.

What is Aerolase?

Aerolase

Manufacturing

Medical Devices & Equipment

Aerolase operates as a global technology leader specializing in laser skin health. The company distinguishes itself as the sole manufacturer of portable, high-power lasers designed specifically for dermatology and aesthetic applications. By prioritizing a contactless treatment methodology, Aerolase addresses critical industry demands for safety, hygiene, and patient comfort across all skin types. Their product suite is engineered to treat a wide array of conditions, including acne, melasma, psoriasis, and onychomycosis, while simultaneously optimizing the profitability of medical practices. By reducing downtime and enhancing treatment outcomes, Aerolase effectively lowers the overall cost of care, positioning itself as a vital player in the evolution of dermatological healthcare delivery.

How much funding has Aerolase raised?

Aerolase has raised a total of $2.2M across 2 funding rounds:

2020

Debt

$1M

2021

Debt

$1.2M

Debt (2020): $1M with participation from PPP

Debt (2021): $1.2M led by PPP

Key Investors in Aerolase

PPP

Public-Private Partnership

What's next for Aerolase?

Looking ahead, the infusion of capital is expected to accelerate the deployment of Aerolase's next-generation laser systems into broader clinical environments. The company is well-positioned to leverage this financial momentum to enhance its research and development pipeline, focusing on further refining its #NoTouchAerolase technology. As the demand for safe, efficient, and portable aesthetic solutions continues to rise, Aerolase is likely to prioritize strategic market penetration and the expansion of its global distribution network. By maintaining its focus on clinical efficacy and physician profitability, the firm is poised to solidify its leadership position, potentially attracting further institutional interest as it scales its operations to meet the evolving needs of the global medical aesthetics market.

See full Aerolase company page

See More Financial Insights